App-Quantinova.ai

Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma

Mireia Bachiller - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Sergio Rutella - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Interferon

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Ana Belén Moreno-Castaño - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

Hemostatic Solution

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Luis Gerardo Rodriguez-Lobato - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Immunol

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Antonio Perez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Lymphocytopenia

Dexamethasone

Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data

Arnon P. Kater - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Georg Hess - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

L-Tyrosine

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Cyclophosphamide

Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Pere Barba - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cytomegalovirus infection

IFN-lambda

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Kate Cwynarski - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Cyclophosphamide

Aina Oliver-Caldes - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)

Mario Boccadoro - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Smoldering myeloma

Cyclophosphamide

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Olaf Penack - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Hydroxyzine

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Alexander P. Boardman - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic kidney disease

N/A

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Paola Ghione - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Axicabtagene ciloleucel

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Bertram Glass - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies

Belén Sierro - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

Axicabtagene ciloleucel

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Eolia Brissot - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

tisagenlecleucel-t

Filters

24923 Abstracts